Mucinous colorectal cancer (CRC) is a unique histologic subtype that remains poorly defined. We aimed to better characterize this subtype of CRC and identified an increased frequency of mutations in GNAS, ERBB2, BRAF, KRAS, and SMAD4 with the mucinous histologic subtype, in addition to increased consensus molecular subtype (CMS) 1 (microsatellite instability immune) and decreased CMS2 (canonical) prevalence. Adverse clinical features included microsatellite instability and synchronous metastatic disease at presentation. Even after controlling for clinical and mutation differences, the mucinous histologic subtype was associated with worse overall survival. Background: The mucinous histologic subtype accounts for 5% to 20% of colorectal cancer (CRC) cases but remains poorly characterized. The present study characterized the baseline characteristics, mutational profile, and clinical outcomes of patients diagnosed with mucinous CRC. Materials and Methods: We identified 1877 patients with metastatic CRC with available histologic findings and molecular profiling and summarized the baseline clinical and pathologic characteristics and overall survival (OS) stratified by the histologic type. The data from separate cohorts with consensus molecular subtype (CMS) and CpG island methylator information were also summarized. Results: The mucinous histologic type was found in 277 of the 1877 patients (14.8%) and was associated with an increased prevalence of microsatellite instability (P < .001) and a right-sided primary (P < .001). An increased frequency of CMS1 (microsatellite instability immune) and lower rates of CMS2 (canonical) were identified, with mucinous compared with nonmucinous adenocarcinoma (P < .0001). Mutations in SMAD4 (P < .001), GNAS (P < .001), ERBB2 (P ¼ .02), BRAF (P < .001), and KRAS (P < .001) occurred at greater frequencies in the mucinous CRC cases, and TP53 (P < .001), APC (P < .001), and NRAS mutations (P ¼ .03) were less common. Univariate (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.17-1.63; P < .001) and multivariate analysis (HR, 1.36; 95% CI, 1.12-1.64; P ¼ .002) demonstrated that the mucinous histologic type is associated with worse OS. The features associated with the mucinous histologic subtype were independent predictors for shorter OS, including BRAF (HR, 1.74; 95% CI, 1.35-2.25; P < .001) and KRAS (HR, 1.42; 95% CI, 1.22-1.65; P < .001) mutations, right-sided location (HR, 1.20; 95% CI, 1.04-1.39; P ¼ .01), and synchronous metastases (HR, 2.92; 95% CI, 2.49-3.42; P < .001). Conclusion: Compared with nonmucinous adenocarcinoma, the mucinous histologic type is associated with a worse prognosis, even when controlling for known prognostic features. This unique biologic behavior should be considered in the treatment and prognostic assessment of patients with CRC.
Introduction
Colorectal carcinomas (CRCs) are a heterogeneous group of neoplasms with varying genetic abnormalities and histologic features. The most common CRC histologic subtypes include adenocarcinoma, mucinous, signet ring cell, medullary, and micropapillary; however, other rare histopathologic variants have been reported. 1 The mucinous subtype accounts for 5% to 20% of all CRC cases 2 and has been defined by the presence of abundant extracellular mucous, which contributes to > 50% of the tumor volume. 3 The carcinogenesis of mucinous carcinoma is not well understood; however, several unique characteristics suggest a pathogenesis distinct from that of nonmucinous colorectal adenocarcinoma. 4 Mucinous CRC tends to overexpress MUC2 and MUC5AC genes, which are oligomeric mucus/gel-forming genes. 5 Mucinous CRC is also more likely to exhibit microsatellite instability (MSI) than is nonmucinous adenocarcinoma. In addition, mucinous CRC has been shown to be associated with an increased prevalence of the CpG island methylator phenotype-high (CIMP-H). 6 Clinically, mucinous CRC has been shown to be associated with an advanced tumor stage at presentation and inferior outcomes compared with nonmucinous adenocarcinoma. 7 In early-stage disease, the rate of angioinvasion is lower with the mucinous histologic subtype; however, it has been associated with poor differentiation and an increased risk of local recurrence. 7 From a mutational perspective, mutations in PIK3CA,
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SMAD4, 9 and BRAF have previously been reported to be more common in mucinous CRC, 6, 10, 11 with mixed reports regarding the mutational frequency of KRAS. 6, 12 TP53 and APC are less frequently mutated in mucinous carcinoma 6 ; however, their mutations have been shown to have a clinical effect on prognosis when present. 13 
Mucinous Differentiation in Metastatic CRC
Despite attempts to characterize the molecular features of mucinous CRC, the inconsistency of current data and small cohort sizes have made it difficult to obtain concrete information. Because the determination of molecular alterations can assist in the development of targeted therapies, 10 the present study aimed to provide a clearer understanding of the relationship between genomic aberrations and mucinous histologic features in CRC and to assess their possible effects on clinical outcome.
Materials and Methods

Patients
After the institutional review board at The University of Texas MD Anderson Cancer Center (MDACC) approved the present study, we reviewed clinical and pathology records of all patients with biopsy proven mCRC who had had a Clinical Laboratory Improvement Amendments 46-gene next generation sequencing panel performed between January 1, 2012 and September 1, 2016. Patients with nonmucinous, nonadenocarcinoma histologic subtypes were excluded, and the remaining 1825 patients were grouped by histologic type (mucinous vs. nonmucinous adenocarcinoma). The inclusion of patients in the mucinous category required the documentation of > 50% extracellular mucin on the pathology reports, and tumors with a mixed signet-ring cell component were excluded from the analysis. The consensus molecular subtypes (CMSs) were evaluated in a separate cohort of 196 patients from MDACC and 412 patients from The Cancer Genome Atlas with previously reported expression data available.
14,15 A previously reported classifier was used to determine the CMS subtype. 15 The data from a third cohort of 459 metastatic CRC patients were reviewed to provide information about CIMP status. These patients were from the ATTACC Program (ClinicalTrials.gov identifier, NCT01196130; colorectal cancer umbrella protocolassessment of targeted therapies against colorectal cancer screening protocol) at the MDACC. Polymerase chain reaction-based pyrosequencing of DNA was performed to examine the methylation status of multiple CpG island loci for each of the tested genes (hMLH1, Mint1, Mint2, Mint31, p14, and p16). The tumors were classified as CIMP-H if 40% of the CpG Island loci were methylated. 16 
Genetic Analysis
Genomic sequencing was performed in the Clinical Laboratory Improvement Amendments environment at the MDACC and used archival formalin-fixed paraffin-embedded samples from either surgical resection or tissue biopsies. Only samples with tumor content > 20% after macrodissection were used for sequencing, and matched normal tissue samples were not sequenced. The assay has been previously described and uses the Ion Torrent AmpliSeq Cancer Panel Primers. Adequately covered amplicons were defined as those with a coverage depth of > 250 reads. The lower limit of detection was estimated at 5% to 10%. 17 
Statistical Analysis
Baseline comparisons of the demographic, clinical, and mutational characteristics were performed across the histologic groups.
These were performed using c 2 , Fisher's exact, or Mann-Whitney U tests. The multiple testing adjustment method by Benjamini and
Hochberg
18 was used to control the false discovery rate. Overall survival (OS) was defined as the interval between the date of diagnosis of metastatic disease and death and was censored at the last follow-up date for patients who were alive. Survival curves were estimated using the Kaplan-Meier method. 19 Univariate Cox proportional hazard (PH) models were used to evaluate the risk factors associated with OS. 20 A multivariate Cox PH model was obtained by first including the variables with P < .20 on univariate analysis. Backward elimination was then performed until all remaining factors had a P value of < .05. Multivariate Cox PH models were constructed to assess the relationships among patient characteristics, mutations, and OS. A further subgroup analysis was performed only among those patients with synchronous or metachronous metastatic disease. The same survival analysis methods were used to assess the relationships among patient characteristics, mutations, and OS within this subgroup. All statistical analyses were performed using R, version 3.3.1.
Results
Association of Mucinous CRC With Clinical and Molecular Characteristics
The demographic and clinical characteristics stratified by histologic type are summarized in Table 1 . Of 1877 CRC cases, 277 (14.8%) were characterized as mucinous by the histologic diagnosis. A total of 391 nonmucinous and 47 mucinous CRC cases had confident CMS calls and confirmed histologic findings in the CMS cohort. The mucinous histologic type in CRC patients was associated with high MSI (MSI-H; P < .001) and a right-sided location (P < .001). Furthermore, a comparison of CMS subtypes identified a significantly greater proportion of CMS1 (microsatellite instability immune), CMS3 (metabolic), and CMS4 (mesenchymal) with mucinous CRC, with CMS2 (canonical) more common with nonmucinous adenocarcinoma (P < .0001; Figure 1 ). We also determined the prevalence of CIMP in a separate cohort of 457 patients with known CIMP status and identified a greater prevalence of CIMP-H tumors with mucinous CRC than with nonmucinous CRC (P ¼ .003). We also confirmed the association of CIMP-H tumors with the mucinous histologic type (95% 
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Association of Mucinous CRC With Mutations
The analysis of the mutational profiles of patients with nonmucinous adenocarcinoma and mucinous CRC yielded strong associations between the histologic type and the frequency of particular mutations (Table 2, Figure 2 ). The greater frequency of GNAS (P < .001), ERBB2 (P ¼ .02), KRAS (P < .001), BRAF (P < .001), and SMAD4 (P < .001) mutations in mucinous CRC was a particularly notable finding. In contrast, the prevalence of TP53 (P < .001), APC (P < .001), and NRAS (P ¼ .03) mutations was significantly lower among patients with mucinous CRC. The association of these mutations with each other in co-occurrence is further expanded in Figure 3 .
Association of Mucinous CRC With Clinical Outcomes
At the end of the follow-up period, 1026 patients (56%) had died of CRC or other causes. The median follow-up duration was 4.3 years, and the 5-year OS rate was 43% (95% CI, 41%-46%; Figure 4 ). Mucinous CRC was found to confer a worse prognosis (hazard ratio [HR], 1.36; 95% CI, 1.12-1.64; P < .001) compared with nonmucinous adenocarcinoma (Figure 4) .
Univariate analysis also identified MSI, right-sided lesions, synchronous metastatic presentation, and mutations in KRAS, BRAF, FBXW7, NRAS, and PIK3CA as predictors of a poor prognosis. Additionally, GNAS (P ¼ .19), ERBB2 (P ¼ .10), and SMAD4 (P ¼ .004) mutations were initially found to be poor prognosticators on univariate analysis but not on multivariate analysis. In the multivariate model, controlling for each of these independent poor prognostic markers, the mucinous histologic subtype was still associated with worse OS (HR, 1.36; 95% CI, 1.12-1.64; P ¼ .002). KRAS (HR, 1.42; 95% CI, 1.22-1.65; P < .001) and BRAF (HR, 1.74; 95% CI, 1.35-2.25; P < .001) mutations, right-sided lesions (HR, 1.20; 95% CI, 1.04-1.39; P ¼ .01), and a synchronous metastatic presentation (HR, 2.92; 95% CI, 2.49-3.42; P < .001) were also shown to be prognostic factors for shorter OS in this model (Table 3) .
Given a HR of 2.92 on multivariate analysis, a metastatic presentation was found to have a particularly strong prognostic effect. Therefore, we performed a dedicated subgroup analysis to assess the clinical outcomes of the 1179 patients who had presented with synchronous metastatic disease and a separate subgroup analysis of the data from those patients who had presented with metachronous metastatic disease. The prognostic variables significantly associated with a worse prognosis in the synchronous metastatic subgroup are summarized in Supplemental Table 1 (available in the online version). Once again, the mucinous histologic subtype was associated with worse OS on univariate (HR, 1.47; 95% CI, 1.20-1.80; P < .001) and multivariate (HR, 1.28; 95% CI, 1.04-1.58; P ¼ .02) analysis.
Figure 2 Prevalence of Mutations According to Histologic
Type. ***P < .001, **P < .02 
However, in patients who had presented with early-stage CRC (stage 1-3), we found inconsistent findings compared with the cohort as a whole. The presence of mucinous histologic features failed to reach statistical significance as a prognostic factor in this subgroup when controlling for other variables on multivariate analysis (Supplemental Table 2 ; available in the online version). In addition, although multivariate analysis of the full cohort did not delineate MSI-H as a significant prognosticator, the results of a subgroup analysis correlated the presence of MSI-H with poorer OS in patients with early-stage (stage 1-3) CRC at presentation (P < .001).
Discussion
Despite the recognition of the mucinous histologic subtype as a well-established clinical entity among CRCs, it remains poorly characterized. Also, the molecular underpinnings and potential vulnerabilities of this histologic type remain unknown. We found an overall incidence of 14.8% in a large cohort of almost 1900 patients. These results concur with previous estimates of 15% in a US-based report 33 and 10% to 20% in other Western populations. 34, 35 We found significant differences in the baseline and molecular characteristics between the mucinous and nonmucinous adenocarcinoma histologic types. In addition to the differences in common mitogen-activated protein kinase alterations, our analysis identified significantly greater frequencies of GNAS, SMAD4, and ERBB2 mutations among the mucinous subgroup. The roles of ERBB2 and GNAS are vaguely understood in mucinous CRC; however, ERBB2 has the potential to bind with MUC4 as a ligand. 36 GNAS and SMAD4 mutations have been noted in other neoplasms of mucinous origin, 37, 38 suggesting their roles in the pathogenesis of mucinous CRC could be important. Previous studies have reported frequent GNAS mutations in the setting of intraductal mucinous neoplasms of the pancreas and mucinous appendiceal carcinoma and also implicating these mutations in the overexpression of gellike mucins. 37, 38 Because these mutations are characteristic of the mucinous subtype, our results might indicate a potential function of mutant GNAS in the pathogenesis of mucinous CRC. Similarly, SMAD4 and ERBB2 mutations might also be associated with mucinous histologic CRC. 9, 39 However, their contribution to its clinical correlates is vaguely understood. High rates of CMS1 were noted among the mucinous CRC cases in our study, which supports a common biology characterized by MSI, right-sided location, and CIMP. We also noted an association with CMS3 and CMS4, with a substantially lower rate of CMS2 than with nonmucinous CRC (6.4% CMS2 in mucinous vs. 49 .9% in nonmucinous; P < .0001). This is an important finding, because CMS2 is the most common subtype found in CRC and characterizes canonical alterations in the WNT pathway with alterations in copy number. 15 Clearly, given the differences in location, microsatellite status, and CMS subtype, the biologic pathways that drive mucinous CRC are distinct from those that drive nonmucinous adenocarcinoma. This introduces the aspect of genetic variation in the presence or absence of a mucinous histologic CRC. The co-occurrence of BRAF mutations with the mucinous subtype in CRC is well-documented in reported studies 6, 12 and further supported by our findings. A similar relationship has been delineated between mucinous differentiation and KRAS mutations, which some have hypothesized might contribute to mucinous differentiation. 12, 40 However, in our data, the association of KRAS and mucinous histologic CRC was modest. Some studies have reported a similarly low incidence of KRAS mutations in association with mucinous carcinoma 6 ; however, this might have resulted from the larger fraction of the patient population presenting with BRAF mutations, which are nearly mutually exclusive with KRAS mutations. 41 The effect of this relationship would be heavily pronounced in a small cohort. Furthermore, the elevated BRAF and KRAS mutation rates in 
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e704 -Clinical Colorectal Cancer December 2018 mucinous tumors were independent predictors of poorer clinical outcome both in our studies and as previously reported. [42] [43] [44] Our evaluation of the baseline characteristics associated with mucinous CRC revealed a significantly greater prevalence of MSI. This agrees with previous studies in confirming the correlation between mucinous histologic features and MSI-H. 6, 45, 46 Previous data have linked MSI with methylation of the promoter region of the MLH1 gene, which relates to the high percentages of CIMP detected with mucinous CRC among our cohort. 6, 47 The relationship between MSI and clinical outcomes in patients with CRC has been largely favorable in the early-stage CRC, although it appears less favorable for patients with metastatic disease. 48, 49 Furthermore, our findings indicate a significant association between the mucinous subtype and right-sided tumor location. However, although some studies have shown similar results, 46,50 other analyses have not. 6 Given the number of adverse features associated with mucinous histologic CRC, it is important to consider whether its negative prognosis results from the molecular subtype or whether it merely results from an association with other negative features. Owing to the size of our cohort, we could control for negative prognostic features in both multivariate models and the subgroup analysis of only those patients who had presented with synchronous metastatic disease. Even after controlling these variables, the mucinous histologic type appeared associated with worse outcomes. 51 Although these various interconnecting negative prognostic factors might still contribute to the negative prognosis of mucinous CRC, our findings suggest that mucinous CRC is a distinct subgroup and that its negative prognosis is not merely the result of an association with these features. Previous data are in agreement with the correlation demonstrated between mucinous CRC and worse clinical outcomes. Despite the size of our study and robust molecular characterization, our findings must be interpreted in the context of the study's limitations. Our analysis is subject to the disadvantages of a retrospective design, lack of adjustment for treatment variables, and the limitation to the 46 genes included on our next generation sequencing panel. Moreover, because our study was conducted at a single institute, population imbalances such as ethnicity and socioeconomic factors were likely present that could also have introduced bias into our cohort. Irrespective of these limitations, the present study with a large cohort has provided validation of several associations seen in smaller studies and also provides valuable new insights into the molecular underpinnings of the mucinous histologic type that we hope will help support the development of precision oncology for this population.
Conclusion
The present study has provided 1 of the largest and most comprehensive analyses of mucinous histologic CRC to date and highlights important differences compared with nonmucinous adenocarcinoma. Not only do these differences contribute to the pathogenesis of mucinous CRC, these differential pathways also appear to affect the prognosis. Because of its poor prognosis, it might be beneficial to approach this subtype as a discrete biologic entity to allow its clinical and molecular distinctions to be incorporated into therapeutic decision-making and prognostic evaluation.
Clinical Practice Points
The carcinogenesis of mucinous CRC is poorly understood; however, unique clinicopathologic characteristics documented in previous reports have suggested a pathogenesis distinct from that of nonmucinous adenocarcinoma. These differences include a greater likelihood of exhibiting MSI, CIMP-H, or advanced tumor stage at diagnosis. Overall, mucinous CRC has been shown to predict for inferior survival outcomes, either independently or in conjunction with adverse prognostic factors such as BRAF mutations. However, the genomic and pathologic characterization of mucinous CRC as a distinct entity requires additional effort. We report novel findings with respect to the increased prevalence of GNAS, ERBB2, and SMAD4 mutations, which might indicate a potential function for these mutant genes in the pathogenesis of mucinous CRC. In addition, the association of mucinous CRC with CMS1 and the lower frequency of CMS2, combined with the inclination of mucinous CRC to present with a right-sided location, MSI, and mutated KRAS and BRAF in our population, indicates that the biologic pathways driving mucinous CRC are distinct from those of nonmucinous adenocarcinoma. The demarcation of this subtype as a discrete biologic entity could have significant clinical implications. Given the independent role of mucinous histologic features as a poor prognostic factor in patients, early recognition of these molecular distinctions might improve effective risk stratification and prognostic evaluation and could be incorporated into therapeutic decision-making in the future. 
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